RxDoctor Payments Data

Uma Saligram, MD

Neurology · Bryan, TXNPI 1770800757

Payments from drug & device makers

$29,190in general payments, 2019–2025

Across 820 payments — averaging $35.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$15K
  • AbbVie$2K
  • UCB, Inc.$1K
  • Novartis$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Biogen$879
  • plus $8K from 50 others

What the payments were for

  • Food & beverage$13,90299%
  • Education$1881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,190 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$144,519
Medicare patients
317
Services billed
2,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4625$132,493
Nurtec OdtRimegepant Sulfate50$88,565
UbrelvyUbrogepant51$74,110
BriviactBrivaracetam26$51,452
QuliptaAtogepant40$48,169
BotoxOnabotulinumtoxina26$36,695
GocovriAmantadine Hcl14$35,489
VimpatLacosamide13$32,717
Emgality PenGalcanezumab-Gnlm32$25,139
Ajovy AutoinjectorFremanezumab-Vfrm23$21,766
NeuproRotigotine16$13,851
HorizantGabapentin Enacarbil21$12,840
Aimovig AutoinjectorErenumab-Aooe17$12,630
Keppra XrLevetiracetam17$11,150
Lacosamide61$7,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$1,730$158,973117 claims
Grifols USA, LLCGamunex-C$29$132,49325 claims
UCB, Inc.Briviact, Vimpat, Neupro$1,186$98,02055 claims
PfizerNurtec Odt$491$88,56550 claims
Arbor Pharmaceuticals, Inc.Horizant$91$12,84021 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$35$4,42426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →